PYFA Stock Overview
Engages in the development, production, and trading of pharmaceuticals primarily in Indonesia.
| Snowflake Score | |
|---|---|
| Valuation | 1/6 |
| Future Growth | 0/6 |
| Past Performance | 0/6 |
| Financial Health | 0/6 |
| Dividends | 0/6 |
PT Pyridam Farma Tbk Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | Rp304.00 |
| 52 Week High | Rp1,545.00 |
| 52 Week Low | Rp81.00 |
| Beta | 1.19 |
| 11 Month Change | 16.92% |
| 3 Month Change | 204.00% |
| 1 Year Change | -63.81% |
| 33 Year Change | -71.05% |
| 5 Year Change | 50.50% |
| Change since IPO | 8.57% |
Recent News & Updates
Recent updates
Shareholder Returns
| PYFA | ID Pharmaceuticals | ID Market | |
|---|---|---|---|
| 7D | 10.9% | -1.6% | -2.8% |
| 1Y | -63.8% | -4.5% | 12.7% |
Return vs Industry: PYFA underperformed the ID Pharmaceuticals industry which returned -4.5% over the past year.
Return vs Market: PYFA underperformed the ID Market which returned 12.7% over the past year.
Price Volatility
| PYFA volatility | |
|---|---|
| PYFA Average Weekly Movement | 15.1% |
| Pharmaceuticals Industry Average Movement | 4.1% |
| Market Average Movement | 5.5% |
| 10% most volatile stocks in ID Market | 12.9% |
| 10% least volatile stocks in ID Market | 2.3% |
Stable Share Price: PYFA's share price has been volatile over the past 3 months compared to the ID market.
Volatility Over Time: PYFA's weekly volatility (15%) has been stable over the past year, but is still higher than 75% of ID stocks.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 1976 | 1,193 | Yan Gwan Lee | www.pyfa.co.id |
PT Pyridam Farma Tbk engages in the development, production, and trading of pharmaceuticals primarily in Indonesia. The company operates in two segments, Pharmaceutical Products, Esthetic, and Toll Manufacturing Services; and Medical Equipments. It supplies medical instruments and equipment, including clinical waste, collection swab, collection tube, innerbox DCA, KF94 mask, parafilm, PCR – extraction kit and extractor machine, speciment bag, sterile container, PCR machine- Gentier 48, and tube stopper.
PT Pyridam Farma Tbk Fundamentals Summary
| PYFA fundamental statistics | |
|---|---|
| Market cap | Rp3.59t |
| Earnings (TTM) | -Rp246.24b |
| Revenue (TTM) | Rp1.34t |
2.7x
P/S Ratio-14.6x
P/E RatioIs PYFA overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| PYFA income statement (TTM) | |
|---|---|
| Revenue | Rp1.34t |
| Cost of Revenue | Rp975.58b |
| Gross Profit | Rp367.84b |
| Other Expenses | Rp614.08b |
| Earnings | -Rp246.24b |
Last Reported Earnings
Sep 30, 2024
Next Earnings Date
n/a
| Earnings per share (EPS) | -20.85 |
| Gross Margin | 27.38% |
| Net Profit Margin | -18.33% |
| Debt/Equity Ratio | 285.2% |
How did PYFA perform over the long term?
See historical performance and comparison